参一胶囊在晚期非小细胞肺癌维持治疗中的效果观察(1)
[摘要]目的 探讨参一胶囊在晚期非小细胞肺癌(NSCLC)维持治疗中的效果。方法 选取2013年7月～2015年10月收治的90例Ⅲb～Ⅳ期NSCLC患者为研究对象，按照随机数字表法分为对照组与研究组，每组各45例。对照组采取培美曲塞药物治疗，研究组采用参一胶囊维持治疗，两组均治疗4个周期。比较两组的总有效率、治疗受益率、KPS评分改善程度以及CD3+、CD4+、CD8+及CD4+/CD8+等免疫功能指标；比较两组不良反应发生情况。结果 研究组总有效率为53.33%，治疗受益率为84.44%，均明显高于对照组的31.11%和66.67%，差异均有统计学意义(P<0.05)。治疗后，研究组患者KPS评分总提高率明显高于对照组，两组的各项免疫功能指标均显著低于治疗前，且研究组高于对照组，差异均有统计学意义(P<0.05)。两组治疗中均未出现严重不良反应。结论 晚期非小细胞肺癌患者采取参一胶囊维持治疗可以明显提高治疗效果、受益率及患者的生存质量，改善机体的免疫功能，值得临床推广应用。
[关键词]参一胶囊；晚期；非小细胞肺癌；维持治疗；效果
[中图分类号] R734 [文献标识码] A [文章编号] 1674-4721(2016)11(c)-0085-04
[Abstract]Objective To invesigate the effect of Shenyi Capsules for advanced non-small cell lung cancer (NSCLC) maintenance treatment.Methods From July 2013 to October 2015，90 cases of advanced NSCLC patients with stage Ⅲb～Ⅳ were divided into control group and study group according to the random number table method，45 cases in each group.Control group was treated with pemetrexed，study group was treated with Shenyi Capsules.Patients of the two groups were treated for four cycles.The rate of total effective，rate of treatment benefit，KPS score，and immune function indexes such as CD3+，CD4+，CD8+，CD4+/CD8+ of the two groups before and after treatment were compared；the adverse reactions of the two groups were compared.Results The total effective rate of the study group was 53.33%，and the rate of therapeutic benefit was 84.44%，which were significantly higher than those of the control group (31.11%，66.67%)，the differences were statistically significant (P<0.05).After treatment，the total increase rate of KPS score in the study group was significantly higher than that of the control group，and the immune function indexes of the two groups were significantly lower than those before treatment，and study group was higher than those of the control group，the differences were statistically significant (P< 0.05)；there was no serious adverse reactions in two groups.Conclusion Shenyi Capsules maintenance treatment can significantly improve the efficiency，the quality of life and immune function of patients with advanced NSCLC，so it is worthy of clinical application.
[Key words]Shenyi capsules；Advanced；Non small cell lung cancer；Maintenance treatment；Effect
肺癌是目前最为普遍的恶性肿瘤之一，在我国其发病率以及死亡率已成為恶性肿瘤之首，并且绝大部分患者为非小细胞肺癌(non-small cell lung carcinoma，NSCLC)，一经确诊大多数患者已为Ⅲb～Ⅳ期，错失了手术最佳时期，而临床上治疗方法主要为放疗及化疗[1-2]。虽然大部分化疗能够控制病情的发展，但是长期放化疗将会对患者的消化系统及血液循环等产生毒副作用，并且治疗效果不显著[3-5]。因此，研究较为有效的治疗方案，延缓患者病情发展，提高生存质量，降低不良反应发生率，将具有重要的研究意义。研究发现中药在NSCLC患者的维持治疗中效果显著，并已引起广泛的关注[6]。参一胶囊在中药中作为Ⅰ类新单体抗癌药物，在胃癌、大肠癌等恶性肿瘤的化疗中起到重要效果。因此本研究针对参一胶囊对晚期NSCLC维持治疗的效果进行研究，取得满意效果，现报道如下。 (刘尊涛 李鸿雁)
[关键词]参一胶囊；晚期；非小细胞肺癌；维持治疗；效果
[中图分类号] R734 [文献标识码] A [文章编号] 1674-4721(2016)11(c)-0085-04
[Abstract]Objective To invesigate the effect of Shenyi Capsules for advanced non-small cell lung cancer (NSCLC) maintenance treatment.Methods From July 2013 to October 2015，90 cases of advanced NSCLC patients with stage Ⅲb～Ⅳ were divided into control group and study group according to the random number table method，45 cases in each group.Control group was treated with pemetrexed，study group was treated with Shenyi Capsules.Patients of the two groups were treated for four cycles.The rate of total effective，rate of treatment benefit，KPS score，and immune function indexes such as CD3+，CD4+，CD8+，CD4+/CD8+ of the two groups before and after treatment were compared；the adverse reactions of the two groups were compared.Results The total effective rate of the study group was 53.33%，and the rate of therapeutic benefit was 84.44%，which were significantly higher than those of the control group (31.11%，66.67%)，the differences were statistically significant (P<0.05).After treatment，the total increase rate of KPS score in the study group was significantly higher than that of the control group，and the immune function indexes of the two groups were significantly lower than those before treatment，and study group was higher than those of the control group，the differences were statistically significant (P< 0.05)；there was no serious adverse reactions in two groups.Conclusion Shenyi Capsules maintenance treatment can significantly improve the efficiency，the quality of life and immune function of patients with advanced NSCLC，so it is worthy of clinical application.
[Key words]Shenyi capsules；Advanced；Non small cell lung cancer；Maintenance treatment；Effect
肺癌是目前最为普遍的恶性肿瘤之一，在我国其发病率以及死亡率已成為恶性肿瘤之首，并且绝大部分患者为非小细胞肺癌(non-small cell lung carcinoma，NSCLC)，一经确诊大多数患者已为Ⅲb～Ⅳ期，错失了手术最佳时期，而临床上治疗方法主要为放疗及化疗[1-2]。虽然大部分化疗能够控制病情的发展，但是长期放化疗将会对患者的消化系统及血液循环等产生毒副作用，并且治疗效果不显著[3-5]。因此，研究较为有效的治疗方案，延缓患者病情发展，提高生存质量，降低不良反应发生率，将具有重要的研究意义。研究发现中药在NSCLC患者的维持治疗中效果显著，并已引起广泛的关注[6]。参一胶囊在中药中作为Ⅰ类新单体抗癌药物，在胃癌、大肠癌等恶性肿瘤的化疗中起到重要效果。因此本研究针对参一胶囊对晚期NSCLC维持治疗的效果进行研究，取得满意效果，现报道如下。 (刘尊涛 李鸿雁)